We are very pleased to introduce and welcome a new IP expert and with him a new topic for our IP training curriculum: Dr. Jörg Thomaier, CEO Bayer Intellectual Property GmbH and Head of IP Bayer Group.
- intellectual property
- Live streaming available
- Executive Agency for Small and Medium-sized Enterprises
- Social media links
- Number of seats
- Entrance fee
- 36 EUR
We are very pleased to introduce and welcome a new IP expert and with him a new topic for our IP training curriculum: Dr. Jörg Thomaier, CEO Bayer Intellectual Property GmbH and Head of IP Bayer Group, will talk about IP and Health - Pharmaceutical IP in the times of COVID-19.
Speaker: Dr. Jörg Thomaier, CEO Bayer Intellectual Property GmbH and Head of IP Bayer Group
Dr. Jörg Thomaier, born in Heidelberg, Germany, obtained his PhD in the field of phosphorus-organometallic Chemistry after studying at the Universities of Freiburg (DE), Utrecht (NL) as well as the ETH Zürich (CH). He joined Bayer straight after his PhD and completed his education as European Patent Attorney after passing the European Qualifying Examination at the European Patent Office in 2001. Since then Thomaier held various positions within Bayer Group like Chief Patent Counsel at Bayer Business Services GmbH establishing a Patent Department within BBS or in 2006 he transferred to Bayer Healthcare AG to become Chief Patent Counsel of said Subgroup. In 2012 Thomaier restructured the Germany based IP Community by establishing the Bayer IP GmbH, encompassing all IP Functions in Germany. With the Go Live of said entity in April 2012 he additionally took on the role as the Managing Director of Bayer IP GmbH.
In today’s global economy, knowledge is emerging as one of the most fundamental economic forces. Strong IP systems can incite funding into knowledge development and, thus, promote innovation. This is particularly relevant for the pharmaceutical industry, which depends on patent protection to support its investments in medical research. Developing a new drug and successfully bringing it to market is a risky, lengthy and expensive venture especially now that COVID-19 created an urgent need for therapeutic innovation!
Main subtopics of the lecture:
- A Public contract Called Patent Law
- Intellectual Property and the Pharmaceutical Industry
- Impact of IP and Real Hurdles in HealthCare
- COVID-19 Special
Level of expertise: Intermediate / Advanced